BRAF and neoplasm: Therefore, germline MMR mutation testing should still be considered in patients with clinical features highly suggestive of LS, and MLH1 epimutation testing should be performed in those with a cancer onset below the age of 60 y.o. and a MLH1-methylated tumor, irrespective of the BRAF mutation status and of the family history.